ArticleCPT: pharmacometrics & systems pharmacology2019
A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins.
Abstract read
In one paragraph
Article in CPT: pharmacometrics & systems pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.Frontiers in immunology · 2020Pooled it
- From permeation enhancer to therapeutic enabler: Advances, applications, and translational perspectives in hyaluronidase-based drug delivery.Materials today. Bio · 2026Review
- Use of Modeling and Simulation to Inform the Development of Monoclonal Antibodies to Treat Moderate-to-Severe Asthma: A Retrospective Review of EMA Centralized Procedure From 2014 to 2024.CPT: pharmacometrics & systems pharmacology · 2026Article
- Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment.Frontiers in immunology · 2026Review
- Role of Antidrug Antibodies in Oncolytic Viral Therapy: A Dynamic Modelling Approach in Cancer Patients Treated with V937 Alone or in Combination.Clinical pharmacokinetics · 2025Article
- Mechanism-Based Modeling Approaches to Quantify the Effect of Immunogenicity on the Pharmacokinetics of Therapeutic Proteins in Drug Development.CPT: pharmacometrics & systems pharmacology · 2025Review
- IQ Survey Results on Current Industry Practices: Part 2-Quantitative Evaluations of Immunogenicity Assessment.Clinical pharmacology and therapeutics · 2025Review
- The Role of Cross-Institutional and Interdisciplinary Collaboration in Defining and Executing a Quantitative Systems Pharmacology Strategy.Handbook of experimental pharmacology · 2025Review
- Towards new approach methodologies for biological therapeutics: a novel model-informed metric to assess immunogenicity risk.Frontiers in immunology · 2025Article
- Conceptual quantitative systems pharmacology framework for supporting clinical trial design in organ-specific autoimmune and rare diseases.Frontiers in immunology · 2025Review
- Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework.The AAPS journal · 2024Article
- QSP Designer: Quantitative systems pharmacology modeling with modular biological process map notation and multiple language code generation.CPT: pharmacometrics & systems pharmacology · 2023Article
- Learn-confirm in model-informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform.CPT: pharmacometrics & systems pharmacology · 2023Article
- Application of quantitative systems pharmacology to guide the optimal dosing of COVID-19 vaccines.CPT: pharmacometrics & systems pharmacology · 2021Article
- Trastuzumab immunogenicity development in patients' sera and in laboratory animals.BMC immunology · 2021Article
- Integration of Omics Data Sources to Inform Mechanistic Modeling of Immune-Oncology Therapies: A Tutorial for Clinical Pharmacologists.Clinical pharmacology and therapeutics · 2020Review
- Immunogenicity in Clinical Practice and Drug Development: When is it Significant?Clinical and translational science · 2020Article
- Where Do PBPK Models Stand in Pharmacometrics and Systems Pharmacology?CPT: pharmacometrics & systems pharmacology · 2020Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Andrzej M KierzekCertara QSP, Certara UK Limited, Sheffield, UK.
Timothy P HicklingBioMedicine Design, Pfizer, Andover, Massachusetts, USA.ORCID 0000-0002-8918-2140
Isabel FigueroaAbbVie Inc, North Chicago, Illinois, USA.
J Cory KalvassAbbVie Inc, North Chicago, Illinois, USA.
Marjoleen NijsenAbbVie Inc, North Chicago, Illinois, USA.
Krithika MohanAbbVie Inc, North Chicago, Illinois, USA.
Geertruida M VeldmanAbbVie Inc, North Chicago, Illinois, USA.
Akihiro YamadaPharmacometrics JP, Clinical Pharmacology and Exploratory Development, Astellas Pharma Inc., Tokyo, Japan.
Hiroyuki SayamaAnalysis & Pharmacokinetics Research Labs, Astellas Pharma Inc., Tsukuba-shi, Japan.
Sachiko YokooAnalysis & Pharmacokinetics Research Labs, Astellas Pharma Inc., Tsukuba-shi, Japan.
Abhishek GulatiPharmacometrics US, Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.
Renu S DhanikulaBristol-Myers Squibb, Princeton, New Jersey, USA.
Jochem GokemeijerBristol-Myers Squibb, Princeton, New Jersey, USA.
Tarek A LeilBristol-Myers Squibb, Princeton, New Jersey, USA.
Craig J ThalhauserBristol-Myers Squibb, Princeton, New Jersey, USA.
Mario GiorgiCertara QSP, Certara UK Limited, Sheffield, UK.ORCID 0000-0001-7763-8545
Maciej J SwatCertara QSP, Certara UK Limited, Sheffield, UK.
Vijayalakshmi ChelliahCertara QSP, Certara UK Limited, Canterbury, UK.
Ben G SmallCertara QSP, Certara UK Limited, Sheffield, UK.
Neil BensonCertara QSP, Certara UK Limited, Canterbury, UK.
Michael WalkerCertara QSP, Certara UK Limited, Sheffield, UK.
Kapil GadkarDevelopment Sciences, Genentech, San Francisco, California, USA.
Valerie QuarmbyDevelopment Sciences, Genentech, San Francisco, California, USA.
Rong DengDevelopment Sciences, Genentech, San Francisco, California, USA.
Andrea FerranteAME Biotechnology Discovery Research, Lilly Biotechnology Center, San Diego, California, USA.
Gemma L DickinsonEli Lilly and Company, Indianapolis, Indiana, USA.
Jan-Stefan Van Der WaltEli Lilly Research & Development, Windlesham, UK.
Lian ZhouEli Lilly and Company, Indianapolis, Indiana, USA.
Xiaoying ChenBioMedicine Design, Pfizer, Cambridge, Massachusetts, USA.
Hannah M JonesBioMedicine Design, Pfizer, Cambridge, Massachusetts, USA.
Jatin NarulaBioMedicine Design, Pfizer, Cambridge, Massachusetts, USA.
Sophie TourdotBioMedicine Design, Pfizer, Andover, Massachusetts, USA.
Thierry LavéRoche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.
Benjamin RibbaRoche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.
Piet H van der GraafCertara QSP, Certara UK Limited, Canterbury, UK.ORCID 0000-0003-1314-3484
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Drug DiscoveryEpitopes, T-LymphocyteHumansModels, BiologicalPharmacology, ClinicalProtein EngineeringProteinsSystems BiologyEpitopes, T-LymphocyteProteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.